Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16578560 | 0.90 | DAO (0.43) | DAOMAOBKCNN4TAAR1HTR2B | |
| SCHEMBL20751137 | 0.89 | SMN1; SMN2 (0.47) | HTTKMT2ADAOMAOBEGFR | |
| SCHEMBL16578866 | 0.85 | DAO (0.40) | HTTDAOMAOBKCNN4EGFR | |
| SCHEMBL17970920 | 0.82 | ADORA2A (0.44) | DAOPOLB | |
| SCHEMBL17970913 | 0.81 | SIGMAR1 (0.45) | L3MBTL1DAOSIGMAR1POLB | |
| SCHEMBL17970918 | 0.78 | LIPG (0.40) | MAPTDAOMAOBKCNN4NR3C2 | |
| SCHEMBL17970877 | 0.76 | KMT2A (0.55) | MAPTKMT2APOLB | |
| SCHEMBL17970910 | 0.76 | SMN1; SMN2 (0.47) | HTTMAPTPOLB | |
| SCHEMBL20751239 | 0.74 | DAO (0.41) | MAPTDAOMAOBKCNN4SIGMAR1 | |
| SCHEMBL16578561 | 0.72 | ALDH1A1 (0.49) | KMT2ADAOSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221963-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | Janssen Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221963-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | PDXK, PNPO, PLPBP | HTT 3821/4885MAPT 1738/4885L3MBTL1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.